Board of Directors
The composition of Novozymes' Board of Directors following the Annual Shareholders' Meeting on February 22, 2017.
Jørgen Buhl RasmussenBorn 1955.
Chairman of the Board since 2017. Adjunct Professor at Copenhagen Business School. Member of the Board since 2011. Member of the Audit Committee. Elected for one year at a time.Board positions
Member: IFC Europe A/S, Axcel Advisory Board, DI's Permanent Committee on Business Policies
Chairman of Nomination and Remuneration Committee
Chairman: F. Uhrenholt A/S
International business and management experience, specifically within sales, marketing, branding and acquisitions Experience in finance and accounting matters.
Agnete Raaschou-NielsenBorn 1957.
Vice Chairman of the Board since 2017. Member of the Board since 2011. Elected for one year at a timeBoard positions
Chairman: Arkil Holding A/S, Brdr. Hartmann A/S
Vice Chairman: Dalhoff Larsen & Horneman A/S, Danske Invest, Solar A/S
Member: Aktieselskabet Schouw & Co., Danske Invest Management A/S, Icopal Holding A/S
Member of Audit Committees:
Aktieselskabet Schouw & Co., Solar A/S
Expertise in business development and acquisitions, macroeconomics and intellectual property rights. Experience in finance and accounting matters.
Heinz-Jürgen BertramBorn 1958.
President & CEO, Symrise AG, Germany. Doctoral degree, PhD (Chemistry). Member of the Board since 2015. Elected for one year at a time.
Member: Rockwool International A/S
International business and management experience, specifically in converting biotechnology research into commercial products and solutions.
Lars GreenBorn 1967.
Senior Vice President, Finance & Operations, Novo Nordisk Inc. (USA), MSc (Business Administration). Member of the Board since 2014. Chairman of the Audit Committee. Elected for one year at a time.Special competencies
In-depth knowledge of the Novo Group's business, international experience from managing global biotech and biopharma companies, and financial and accounting expertise.
Mathias UhlénBorn 1954.
Professor, the Royal Institute of Technology (Kungliga Tekniska Högskolan), Sweden, and the Technical University of Denmark (DTU). Member of the Board since 2007. Elected for one year at a time.Board positions
Chairman: Atlas Antibodies AB, Antibodypedia AB
Vice Chairman: Affibody AB
Member: Alligator AB, Bure Equity AB, SweTree Technologies AB
Broad experience in research and biotechnology.
Kim StrattonBorn 1962.
Head of International Commercial, Shire International GmbH (Switzerland). Member of the Nomination and Remuneration Committee
Broad international commercial experience, including in sales and marketing, emerging markets, innovation pipeline management and sustainability.
Kasim KutayBorn 1965.
CEO, Novo A/S
Broad experience within biotechnology, and in mergers and acquisitions, as well as financial and accounting expertise.
Lena Bech HolskovBorn 1967.
Safety Adviser. Employee representative. Member of the Board since 2013. Elected for four years at a time.
Anders Hentze KnudsenBorn 1959.
Senior Operator. Employee representative. Member of the Board since 2013. Elected for four years at a time.
Lars Bo KøpplerBorn 1962.
Technician. Employee representative. Member of the Board since 2010. Elected for four years at a time.
Employee elected member of the board of Novo Nordisk Foundation since 2014. Elected for a four year period.